Skip to content
10-Q

Quarterly Report

LEXICON PHARMACEUTICALS, INC. LXRX

0001062822-25-000029

← back to feed
Filed
May 14, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 9, 2025 363.18M sh
Long Term Debt Q1 2025 · Mar 31, 2025 $58.64M
Long Term Debt Q1 2025 · Dec 31, 2024 $100.3M
Short Term Debt Q1 2025 · Mar 31, 2025 $42.06M
Short Term Debt Q1 2025 · Dec 31, 2024 $0
Short Term Investments Q1 2025 · Mar 31, 2025 $131.95M
Short Term Investments Q1 2025 · Dec 31, 2024 $171.3M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $62.89M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $66.66M
Stockholders Equity Q1 2025 · Mar 31, 2025 $123.03M
Stockholders Equity Q1 2025 · Dec 31, 2024 $145.95M
Current Liabilities Q1 2025 · Mar 31, 2025 $110.69M
Current Liabilities Q1 2025 · Dec 31, 2024 $45.25M
Total Liabilities Q1 2025 · Mar 31, 2025 $174.64M
Total Liabilities Q1 2025 · Dec 31, 2024 $152.47M
Current Assets Q1 2025 · Mar 31, 2025 $245.81M
Current Assets Q1 2025 · Dec 31, 2024 $246.19M
Total Assets Q1 2025 · Mar 31, 2025 $297.67M
Total Assets Q1 2025 · Dec 31, 2024 $298.42M
Revenue Q1 2025 · Mar 31, 2025 $1.26M
Revenue Q1 2025 · Mar 31, 2024 $1.09M
Shares Diluted Q1 2025 · Mar 31, 2024 245.39M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$55.13M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.20
Eps Basic Q1 2025 · Mar 31, 2024 −$0.20
Sga Expense Q1 2025 · Mar 31, 2024 $32.06M
Rd Expense Q1 2025 · Mar 31, 2024 $14.37M
Net Income Q1 2025 · Mar 31, 2024 −$48.4M
Operating Income Q1 2025 · Mar 31, 2024 −$45.33M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $31K